ABSTRACT
35% for GFAP. PPVs ranged from 75.5% for S-100b to 96.5% for GFAP. Negative LR ranged from 0.59 for GFAP to 0.71 for UCH-L1, with positive LR ranging from 1.0 for both UCH-L1 and S-100b to 8.7 for GFAP.
Conclusion:
A single serum concentration of GFAP, UCH-L1, or S-100b within 6 hours of head injury may be useful in identifying and stratifying the severity of brain injury in emergency department patients with head trauma, but cannot reliably exclude a diagnosis of concussion. A positive GFAP was associated with the presence of concussion.
T he Centers for Disease Control and Prevention has estimated that 2.5 million traumatic brain injuries (TBIs) occur in the United States annually. 1 Mild traumatic brain injury (mTBI) has been estimated to account for 70% to 90% of all TBI. 2 Many of these patients present to the emergency department (ED) for care. The hallmark of mTBI is a transient reduction in brain function at the time of head injury, but there is currently no single objective criterion standard for diagnosing mTBI. This is a particular problem for the subset of head injured patients who may have had a transient alteration in neurologic function, but who at presentation to the ED have a Glasgow Coma Scale (GCS) of 15 and no focal neurologic deficits. A number of groups and organizations have developed working definitions for mTBI (often referred to as concussion), including the Centers for Disease Control and Prevention, 3 the World Health Organization, 4 the American Congress of Rehabilitation Medicine (ACRM), 5 and the American Academy of Neurology. 6 These definitions, based on various clinical signs and symptoms, all share the key criteria of loss of consciousness (LOC), posttraumatic amnesia, or confusion and may be associated with specific somatic, emotional, or cognitive complaints.
An easily performed objective test with high sensitivity and reasonable specificity could be a significant advance in diagnosing this disorder and may aid in prognosis, treatment, and medical decision-making (particularly return to work or play). The primary objective of this study was to determine if a single serum concentration of glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), or S-100b (within 6 hours of head injury) can distinguish between head-injured subjects who meet criteria for mTBI (concussion) and those who do not.
METHODS

Study Design
This was a planned secondary analysis of a prospective, multicenter, observational clinical trial partially funded through the Department of Defense, entitled 'Biomarkers of Mild and Moderate Traumatic Brain Injury," ClinicalTrials.gov. identifier NCT01295346. The parent trial compared GFAP, UCH-L1, and S-100 b to differentiate head injured patients with normal computed tomography (CT) of the head from those with an acute injury on head CT. 7 Our study analyzed the subset of subjects with a GCS of 13 to 15 inclusive, with the aim of determining sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of these biomarkers to differentiate subjects with concussion from those without.
Institutional review board approval was obtained at each study site and each site also obtained approval by the ethics board of the U. S. Army Medical Research and Material Command Office of Research Protections Human Research Protection Office Department of Defense. Informed consent was obtained from each subject.
Study Setting and Population
Patients from 18 to 80 years of age, seen at one of seven study site hospital EDs for a deceleration or blunt head injury were eligible. Eligible patients had an initial GCS of 13 to 15 inclusive and underwent emergency head CT and had venipuncture for blood sampling within 6 hours of injury. Table 1 details the full inclusion and exclusion criteria.
Study Protocol
Baseline data obtained included demographics, medical history, GCS scores, mechanism of injury, and postinjury signs and symptoms including LOC and posttraumatic amnesia.
Serum Sampling and Handling
Blood samples were collected at study enrollment and every 6 hours, to time of discharge or to 24 hours (maximum of five samples during index visit). Samples were processed and the resulting serum was stored at -80°C and shipped on dry ice to a central repository for storage, until testing. This study evaluates the diagnostic characteristics of the initial serum sample obtained within 6 hours of head injury.
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Measurements
Serum Analysis for GFAP, UCH-L1, and S-100b. Samples were analyzed for UCH-L1 and GFAP using an enzyme-linked immunosorbent assay, by technicians blinded to clinical data and CT results. The assay utilizes a sandwich antibody technique with a chemiluminescent substrate that is then measured by a luminometer. Details regarding this technique can be found in a previous publication.
7 S-100b concentrations were determined using an electrochemiluminescence immunoassay designed for in vitro diagnostic testing (Cobas 6000, Roche). Results for S-100b are given in lg/L, with the standard normal reference intervals of 0.00 to 0.09 lg/L.
The reported limit of detection (LOD) using these assays is 20 pg/mL for GFAP, 10 pg/mL for UCH-L1, and 5 pg/mL for S-100b. The lower limit of quantification (LLoQ) for GFAP and UCH-L1 is 30 pg/ mL. There is no reported LLoQ for S-100b.
Serum concentrations for all biomarkers are reported in pg/mL. Assay results were not available to the treating clinician and were not used to guide treatment.
Head CT Scans. Two neuroradiologists, blinded to all clinical and laboratory data except subject age and sex, reviewed all of the study subjects' CT scans for the presence of an acute intracranial injury. Any discrepancy with respect to the presence of an acute intracranial injury was adjudicated by a third radiologist. Inter-rater reliability between the two primary radiologists was determined using Cohen's Kappa statistic.
Post-Concussion Symptom Assessment. Subjects were also evaluated using the Rivermead PostConcussion Symptoms Questionnaire (RPQ), which consists of 16 items regarding symptoms of concussion, with a Likert scale for each symptom ranging from "0" (not experienced at all) to "4" (severe problem). 8 Previous Rasch analysis of the 16-item RPQ and our own analysis of the RPQ in the ED setting support the use of three items (headache, dizziness, and nausea) rather than all 16 to indicate concussion in the acute setting. 9, 10 We determined the RPQ 3 score, and based on our previous study, consider a score greater than 3 (out of a maximum of 12) to be indicative of concussion. 10 We report our results with the RPQ data in the supplemental files.
Outcomes
We compared median serum biomarker concentrations in three groups: 1) complicated mTBI, (GCS of 13-15 inclusive, one or more clinical criteria for concussion [LOC, posttraumatic amnesia, confusion in the ED], and the presence of an acute intracranial injury on head CT); 2) uncomplicated mTBI (GCS of 13-15 inclusive, one or more of the clinical criteria for concussion, and no evidence of an acute intracranial injury on head CT); and 3) no mTBI (GCS = 15, normal head CT, no LOC, no amnesia, and no confusion).
The primary objective was to determine if a single serum concentration of GFAP, UCH-L1, or S-100b (within 6 hours of head injury) can help differentiate, among subjects who sustained a potential head injury, those with mTBI from those without. We also compare the area under the receiver operating curve (AUC) and test characteristics (sensitivity, specificity, NPV, PPVs, and negative and positive likelihood ratios [LRs]) for each of these biomarkers to differentiate subjects with mTBI, as currently defined, from those with no mTBI.
5,11
Data Analysis and Reporting Baseline demographics and clinical findings were compared between the three patient groups using proportions and means (standard deviation [SD]) or medians (with 25th and 75th percentiles) where appropriate. Median biomarker concentrations with interquartile ranges across the three groups were calculated and visually illustrated using a box and whisker plot. The Kruskal-Wallis test was used to compare median serum biomarker concentrations across the three groups. When Kruskal-Wallis was significant, pairwise The subject was between 18 and 80 years of age (inclusive). Sustained an acceleration/deceleration or closed injury to the head, either self-reported or witnessed. Presented to an ED within 4 h of injury. Had an initial GCS score of 13-15 in the ED, performed by trained study personnel. Had a head CT as part of routine care.
Exclusion criteria
Participation in another clinical study that may affect the results of either study. Time of injury could not be accurately determined. Primary diagnosis of ischemic or hemorrhagic infarct.
Venipuncture not feasible. Blood donation within 1 wk of screening. The subject was otherwise determined medically unsuitable for study participation.
two-sided multiple comparisons were performed using the Dwass, Steel, Critchlow-Fligner method. [12] [13] [14] For our analysis, serum concentrations at or below the LOD were assigned the value of the LOD. Serum concentrations above the LOD but less than or equal to the LLoQ were assigned the LLoQ value. This "rounding up" procedure was thought to be a more conservative approach. We performed a second analysis calculating sensitivity, specificity, NPV, PPV, and negative and positive LRs rounding down (assigning all values above the LOD but less than or equal to the LLoQ to the LOD value) to determine if it made a significant difference in the results. Two separate analyses were performed: the first compared all mTBI subjects to nonconcussed subjects, and the second compared only uncomplicated mTBI subjects to nonconcussed subjects.
We determined the sensitivity, specificity, NPV, PPV, and LRs for each biomarker to detect (or predict) all mTBI (complicated and uncomplicated) versus no mTBI, using cut points that would maximize sensitivity, down to the LLoQ for GFAP and UCH-L1 (30 pg/mL). Since there was no reported LLoQ for S-100b, we chose a serum concentration (35 pg/mL) that would maximize sensitivity, while maintaining a median specificity of at least 5%.
Logistic regression was used to determine AUC with 95% confidence intervals (CIs) for all three biomarkers. A nonparametric approach was used to compare the correlated receiver operating characteristic (ROC) curves without adjustments for pairwise comparisons. 15 The test of equality for the ROC curves was performed using a chi-square statistic with the degrees of freedom based on the number of comparisons (ranging from 2 to 6). Because this was a secondary analysis, no power calculations were performed.
All data analyses were performed using SAS 9.4 and R 3.2, with p < 0.05 denoting statistical significance. Recommended guidelines for reporting results of diagnostic tests (STARD) were followed. 16 
RESULTS
The study enrolled 290 patients between January 1, 2011, and December 19, 2011, 40 of whom were excluded for various reasons (Figure 1 ). Of the remaining 250 subjects, three had an initial GCS < 13 and were excluded from our definition of mTBI. The final sample used in the primary analysis for GFAP and UCH-L1 consisted of 247 patients (Figure 1) . S-100b concentration was only measured in 229 subjects because of an insufficient volume of serum to analyze all three biomarkers, limiting our comparison between all three biomarkers to this subgroup.
There were 188 subjects with a mTBI, based on the ACRM criteria (excluding RPQ results), leaving 59 subjects in the no mTBI group. Of 188 mTBI subjects, 34 (18.1%) had an acute abnormality on head CT, falling into the category of complicated mTBI. The remaining 154 had uncomplicated mTBI. There were no subjects in the no mTBI group with a positive CT scan. The kappa statistic for inter-rater reliability between the two primary neuroradiologists for the presence of an acute injury on CT was 0.82 (95% CI = 0.71-0.91).
When an RPQ score greater than 3 was also used to define mTBI, 214 subjects had mTBI and 33 did not. Results in the text are based on the 188 subjects that meet the consensus definition of mTBI (i.e., concussion) excluding the RPQ score. 5, 11 Results using RPQ score can be found in the supplemental material.
Demographic and clinical characteristics of the patient population, stratified by severity of injury, can be seen in Table 2 . Median serum biomarker concentrations, with interquartile range, across the three subgroups of injury severity can be seen in Table 3 and Figure 2 . Median biomarker concentrations were lowest in the no mTBI subgroup and progressively and significantly increased in the subgroups with uncomplicated and complicated mTBI. These differences were statistically significant (p < 0.0001).
All three biomarkers significantly classified mTBI versus no mTBI with the following AUCs: GFAP, 0.70 (95% CI = 0.64-0.77); S-100b, 0.69 (95% CI = 0.61-0.77); and UCH-L1, 0.65 (95% CI = 0.58-0.74; Figure 3A ). The AUCs for GFAP, UCH-L1, and S-100b did not differ significantly from each other (p = 0.17). Pairwise comparisons were not significant.
All three biomarkers significantly classified uncomplicated mTBI versus no TBI with the following AUCs: GFAP, 0.66 (95% CI = 0.59-0.74); S-100b, 0.65 (95% CI = 0.57-0.73); and UCH-L1, 0.60 (95% CI = 0.53-0.71; Figure 3B ). The AUC for GFAP, UCH-L1, and S-100b did not differ significantly from each other (p = 0.16).
When including an RPQ score greater than 3 as a criterion for mTBI, only GFAP had a significant AUC (0.68 for all mTBI vs. no mTBI and 0.64 for uncomplicated mTBI vs. no mTBI; Data Supplement S1, available as supporting information in the online version of record of this paper, which is available at http://online library.wiley.com/doi/10.1111/acem.13174/full).
Sensitivity, specificity, PPV, NPV, and negative and positive LRs for all mTBI versus no mTBI for each biomarker can be seen in Table 4 . The biomarker concentration used in this analysis was chosen to maximize sensitivity down to the LLoQ for GFAP and UCH-L1 and to maximize sensitivity for S-100b while maintaining a specificity of at least 5%. S-100b and UCH-L1 had high sensitivity, but low specificity, low NPV, low PPV, and unhelpful negative and positive LRs. GFAP had lower sensitivity than the other biomarkers, but had high specificity, PPV, and positive LR. The rounding down method of calculation lowered sensitivity and raised specificity for both GFAP and UCH-L1 (Table 4) . Since S-100b has no reported LLoQ, we did not use rounding to calculate test characteristics. The sensitivity analysis using only the 229 subjects who had all three biomarkers obtained for analysis had similar results to our larger analysis, with a cutoff value for GFAP concentration of 30 pg/mL having a NPV for mTBI of 36.2% (95% CI = 28.5-44.5) and a PPV of 96.3% (95% CI = 89.4%-99.2%).
DISCUSSION
The majority of sustained head injuries result in mild TBI, without acute CT findings, and recovery is usually rapid. 2 However, there is a subset of patients that shows a somewhat longer trajectory of improvement. 17 It has also been shown that repeated mild brain injuries may lead to persistent cognitive impairment as well as to a constellation of postconcussive symptoms. 18, 19 Thus, diagnosing concussion has important implications for follow-up, return-to-work or play instructions, and public health. Data are reported as percentages. No mTBI defined by a GCS score of 15, no loss of consciousness, no amnesia, no confusion on exam, and a normal head CT. CmTBI = complicated mild traumatic brain injury, defined the same as uncomplicated mTBI with the exception that the patient had an acute injury on head CT; GCS = Glasgow Coma Scale; LOC = loss of consciousness; UmTBI = uncomplicated mild traumatic brain injury, defined by GCS > 12, one or more signs of concussion above, and a normal head CT. Data are reported as median (IQR). We used the Kruskal-Wallis test to compare the median biomarker concentration across all three categories of brain injury (none vs. uncomplicated vs. complicated) and if significant used the Dwass, Steel, Critchlow-Fligner (DSCF) method for the pairwise comparisons. [22] [23] [24] In the no mTBI group, the median serum concentration and IQR for GFAP was at its LOD. This was not the case for either S-100b or UCH-L1. CmTBI = complicated mTBI, defined by GCS 13-15, one or more signs of concussion, and an abnormal head CT; GFAP = glial fibrillary acidic protein; IQR = interquartile range; LOD = limit of detection; UCH-L1 = ubiquitin carboxyl-terminal hydrolase L1; UmTBI = uncomplicated mTBI, defined by GCS 13-15, one or more signs of concussion, and a normal head CT.
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Multiple biomarkers have been evaluated as a diagnostic test in patients with suspected TBI, with S-100b being the most widely studied. However, almost all of these studies have examined the usefulness of biomarkers in predicting an acute injury on head CT. [20] [21] [22] [23] [24] [25] [26] S100b has been shown to have high sensitivity, but poor specificity for predicting a positive head CT in headinjured subjects, 20, 21 and may be "falsely" elevated in the presence of extracranial injuries. 22 Two other biomarkers, GFAP and UCH-L1, were predictive of acute intracranial lesions on CT and the need for neurosurgical intervention. 7, 24, 26 One previous study in patients with mTBI found early serum GFAP concentration, but not S-100b, was correlated with return to work at 6 months. 27 We are not aware of any reports that evaluate the usefulness of serum neuronal biomarkers to diagnose mTBI across the spectrum of head-injured patients.
Mild TBI is a heterogeneous entity 28, 29 A GCS of 13 is more likely to be associated with acute CT findings than is a GCS of 15. 29, 30 Previous studies have also shown that a positive head CT often portends a worse prognosis, even in patients with similar clinical presentations. 31, 32 This has led some TBI researchers to consider a reclassification of head-injured patients into mild head injury (defined as a GCS [13] [14] and minor head injury (defined as GCS of 15). 33 It is in this latter group that the diagnosis of a brain injury is most challenging. Patients who experience an acceleration/deceleration or blunt impact to the head, with an initial GCS of 15 and no abnormalities on CT, may or may not have suffered an injury to the brain. The American Academy of Neurology and the American Society for Sports Medicine have similar definitions for concussion, summed up as " . . . a complex pathophysiological process affecting the brain, induced by traumatic biomechanical forces." 34 The diagnosis is based on a constellation of clinical signs and symptoms. 35 Although LOC is sufficient to diagnose concussion, it is not necessary. Alterations in memory and orientation, without LOC, are also considered hallmarks of concussion. 35 These signs may be so transient as to be gone by the time someone reaches the ED. Therefore, the diagnosis of concussion in the ED is problematic. We used selfreport and, whenever available, bystander or EMS report, for any LOC or amnesia (retrograde), as well as our own examination. Confusion, although an indicator of concussion, was less reliably documented and, unless found to be present in the ED, was not used to diagnose concussion in this study. The addition of the RPQ score, which assesses for somatic, emotional, and cognitive symptoms, may identify the presence of a concussion when other clinical criteria are absent; however, this particular instrument was not intended for the assessment of concussion in the acute setting. 8 When mTBI was defined only by the three clinical criteria of LOC, amnesia, or confusion we found a significant difference in the median serum concentration for all three biomarkers in patients with versus those without mTBI. Further, there was a stepwise increase in the median serum concentration of all three biomarkers as the clinical severity of the brain injury increased. Patients with complicated mTBI and lower GCS scores had the highest median biomarker concentrations, followed by those who met criteria for mTBI, but had GCS scores of 15 and no acute findings on head CT, followed finally by those with a normal head CT and a GCS of 15 and who did not meet any of the consensus criteria for concussion. Nonetheless, there was a great deal of variability, particularly in the uncomplicated mTBI group. This may be due to the lack of CT sensitivity for acute traumatic intracranial lesions. 36 It is possible that had MRI been performed many of the outlier subjects might have had intracranial abnormalities identified. Variability and overlap was lower for GFAP than it was for S-100b and UCH-L1 in all groups.
Subjects who met none of the consensus criteria for concussion, but met the definition of mTBI based on acute somatic symptoms alone (an RPQ-3 score > 3), had similar median serum biomarker concentrations to those of the nonconcussed group above (Table 3 and Data Supplement S2, available as supporting information in the online version of record of this paper, which is available at http://onlinelibrary.wiley.c om/doi/10.1111/acem.13174/full). Only the GFAP concentration differentiated between the 180 subjects with uncomplicated mTBI and the 33 nonconcussed subjects based on RPQ scores (Data Supplement S2).
There are published data regarding diagnostic threshold levels for the three biomarkers we evaluated regarding their ability to exclude a positive head CT in head injured patients. 7, [24] [25] [26] 37 These thresholds are 0.1 lg/L (100 pg/mL) for S-100b and range between undetectable levels and 35 pg/mL for GFAP and 40 to 170 pg/mL for UCH-L1. One might expect that to exclude a concussion without a positive head CT would require even lower threshold values. The current LOD and LLoQ for UCH-L1 and particularly for GFAP may present an obstacle in their use to exclude mTBI. In our primary analysis, we chose to round up values that were less than the LOD or LLoQ. Repeating the analysis using a rounding down method lowered sensitivity and raised specificity and PPV (Table 4 ). The PPV of GFAP in this study was 96% to 100% (depending on whether the analysis used the rounding up or rounding down approach), so a All mTBI (complicated + uncomplicated) defined as GCS 13-15, meeting one or more criteria for mTBI as noted in the text, and includes those with either a normal or an abnormal head CT. No mTBI is defined as GCS = 15, no LOC, no amnesia, and no documented confusion. (B) ROC curves for all biomarkers (uncomplicated mTBI vs. no mTBI). Uncomplicated mTBI is defined as GCS 13 to 15, meeting one or more criteria for mTBI as noted in the text, and having a normal head CT. No mTBI is defined as GCS = 15, no LOC, no amnesia, and no documented confusion. GCS = Glasgow Coma Scale; GFAP = glial fibrillary acidic protein; mTBI = mild traumatic brain injury; ROC = receiver operating characteristic; UCH-L1 = ubiquitin C-terminal hydrolase. [Color figure can be viewed at wileyonlinelibrary.com] ACADEMIC EMERGENCY MEDICINE • June 2017, Vol. 24, No. 6 • www.aemj.org positive test appears good at ruling in disease. However, neither GFAP nor any other biomarker had a high enough NPV (range = 31%-35%), to rule out disease.
Further study is required to determine optimal timing of serum sampling and whether repeat testing or combination testing will improve diagnostic or prognostic capability. In future prospective studies it will also be important to use symptom scores and neurocognitive function at longer-term follow-up as a more ideal outcome on which to test biomarker predictive value.
LIMITATIONS
The most obvious limitation to this study is the lack of a criterion standard for the diagnosis of concussion. Head CT and GCS are insensitive to concussion, so we used as the reference standard the consensus definition of concussion agreed upon by many experts across a number of disciplines. The study population consisted of adults who had a documented mechanism of injury that would be reasonably expected to potentially cause brain trauma, such that the treating physician, without regard to the study, felt that a head CT was indicated. This may have led to a sampling bias toward more severe injury since patients who did not have a head CT were not eligible for the study. Since we did not have noninjured controls in the study we do not know how this group would have differed from our "no mTBI" group. It is possible that patients who sustain an acceleration/deceleration or blunt trauma to the head may have subclinical brain injury even without symptoms. However, the intent is to use neuronal biomarkers precisely in the population that has sustained a potential brain injury; thus we feel that the no mTBI (nonconcussed) group, as defined, serves as a reasonable control. We examined a single time point for each biomarker (within 6 hours of injury), and based on the kinetics of the various biomarkers, the relative sensitivity and specificity may differ with sampling time.
CONCLUSION
A single serum concentration of glial fibrillary acidic protein, ubiquitin carboxyl terminal hydrolase L1, or S100b within 6 hours of head injury may be useful in identifying and stratifying the degree of brain injury in ED patients with head trauma, but cannot reliably exclude a diagnosis of concussion. Although the area under the receiver operating curve for all biomarkers, including glial fibrillary acidic protein, to differentiate subjects with mild traumatic brain injury from those with no mild traumatic brain injury was modest, the positive predictive value and the positive likelihood ratio for glial fibrillary acidic protein were high and may be helpful in identifying the presence of concussion. Threshold values for GFAP and UCH-L1 are at the LLoQ; the threshold value for S-100b was chosen for maximum sensitivity, with a specificity of >5%. GFAP = glial fibrillary acidic protein; LLoQ = lower limit of quantification; NPV = negative predictive value; PPV = positive predictive value; UCH-L1 = ubiquitin carboxyl-terminal hydrolase L1. *These results used the "rounding-up" method for serum concentrations below the LOD and between the LOD the LLoQ. †These results used the "rounding-down" method for serum concentrations between the LOD the LLoQ. ‡Data are reported as percent (95% CI). §This value uses a specificity of 99% rather than 100% to avoid a "0" in the denominator.
